In the COVID-19 era, let’s keep an eye on clinical trials in Africa

dc.contributor.authorAgoro, Rafiou
dc.contributor.departmentMedical and Molecular Genetics, School of Medicineen_US
dc.date.accessioned2020-08-17T15:29:51Z
dc.date.available2020-08-17T15:29:51Z
dc.date.issued2020-07-28
dc.description.abstractDue to the high contagiousness of COVID-19 and the lack of an effective medicine, governments and companies are urging their teams to develop new vaccine and therapy with the noble mission to protect us from COVID-19 and preserve our economic achievements. However, under the current pandemic circumstances, we cannot exclude the possibilities that some scientists violate clinical trials rules and guidelines to accelerate new vaccine and medicine development. Low-income countries, notably Africans, could be preferred as a basis for experimentations on human subjects due to the lack of stringent policies in comparison to their high-income counterparts.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationAgoro, R. (2020). In the COVID-19 era, let’s keep an eye on clinical trials in Africa. Journal of Global Health, 10(2). http://www.jogh.org/documents/issue202002/jogh-10-020312.pdfen_US
dc.identifier.urihttps://hdl.handle.net/1805/23623
dc.language.isoen_USen_US
dc.publisherInternational Society of Global Healthen_US
dc.relation.journalJournal of Global Healthen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourcePublisheren_US
dc.subjectCOVID-19en_US
dc.subjectClinical Trialsen_US
dc.subjectHuman Subjectsen_US
dc.subjectEthicsen_US
dc.subjectAfricaen_US
dc.titleIn the COVID-19 era, let’s keep an eye on clinical trials in Africaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Agoro2020IntheCOVID-19.pdf
Size:
792.16 KB
Format:
Adobe Portable Document Format
Description:
Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: